Scientists peer into the brain to see how ADHD drugs work

NCT ID NCT04781972

Recruiting now Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025

Summary

This study aims to find brain-based markers that can predict how well people with ADHD will respond to the medication methylphenidate (Ritalin). Thirty adults with ADHD will receive a single dose of the drug or a placebo, then undergo brain scans and thinking tests. The goal is to measure changes in brain activity and chemical levels, which could help develop better treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD - COMBINED TYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins School of Medicine
RECRUITING

Baltimore, Maryland, 21205, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD - COMBINED TYPE